BVT Aktienanleihe MRK 28.06.2024/ DE000VM0BT10 /
5/15/2024 8:01:40 PM | Chg.+0.790 | Bid9:57:13 PM | Ask9:57:13 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
100.070EUR | +0.80% | - Bid Size: - |
- Ask Size: - |
MERCK KGAA O.N. | 162.55 EUR | 6/28/2024 | Call |
GlobeNewswire
12:00 AM
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/15
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VIS...
GlobeNewswire
5/15
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
GlobeNewswire
5/15
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/15
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
5/7
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
5/6
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
3/4
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
12/21/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
12/14/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
10/17/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA